The follow-up momentum of three new drug varieties approved by HISCO in half a month is not decreasing

Sichuan hisic, a subsidiary of Tibet hisic Pharmaceutical Group Co., Ltd., recently received the approval document for drug registration issued by CFDA for the national class 6 chemical drug "Flupentixol tablets" (gyzz h20153014) and its API "Flupentixol hydrochloride" (gyzz h20150004) and "gyzz h20150005" At the early stage, HISCO announced on January 24 and 29 that it had obtained the registration approval documents of polyprizine granules and Cefmetazole sodium for injection Flupentixicine tablet is a large variety of psychiatry, with relatively wide indications The market space is large The indications of flupentixicine tablet are mainly antidepressant and anxiety, with large market space In the early stage, only one manufacturer in Lingbei, Denmark, had approval, and the commodity name is Deanxit Kangzhe pharmaceutical is the general agent of delixin, with sales volume of 102 million US dollars in 2013, an increase of 28% in the first half of 2014, reaching 385 million yuan (RMB) In early January 2015, Hainan Yier obtained the production approval Sichuan hisico was approved as the third Therefore, the company and Hainan Yier almost enter the market at the same time Considering the indications of the product, the company's sales ability and the opportunity to enter the market, we believe that the product will make outstanding contribution to the company's growth in the next two years with the help of a new round of bidding See the following analysis for details of this product Recently, three varieties have been approved; there are still varieties worthy of attention In recent years, the company has been approved with polyprizin granules, Cefmetazole sodium and flupentixicillin, which has opened the new drug prelude of this year Polyprizin is a product of general medicine upgrading Its indication is mainly gastric ulcer It is a protective agent of gastric mucosa with multiple mechanisms The second company has obtained the approval, and the market refers to bismuth agent However, as an upgraded product, the company will have the advantages of quality and price In addition, there are still a number of key varieties worthy of attention in the future this year Arginine glutamate injection has been notified to the Certification Center for on-site inspection on January 7, 2015, and is currently in the stage of on-site inspection 13 kinds of vitamins were in the review stage of supplementary data, ranking 57 Parenteral nutrition injection (25) is in the process of supplementary data review, ranking 25 Chloroacetyl levocarnitine tablets are in the review of new materials, ranking 26 We note that CDE recruited another 53 reviewers in January 2015, including 44 reviewers, following the recruitment of 20 reviewers in October 2014 Therefore, we believe that drug review is bound to accelerate, and hisilico will benefit significantly.